12 July 2024 : Clinical Research
Efficacy and Safety of Sacubitril/Valsartan in Hemodialysis Patients with Chronic Heart Failure: A Retrospective Study at a Single Center
Zhuan'e Yao ABCDEFG 1,2, Pengbo Wang ABCDE 1, Qinjuan Fu BD 1, Qiong Song BC 1, Ai Liu DF 1, Huan Li BCD 1, Wei Wang DF 1, Peng Zhang ACDEF 2*DOI: 10.12659/MSM.943529
Med Sci Monit 2024; 30:e943529
Table 1 Baseline demographics and clinical characteristics before sacubitril/valsartan treatment.
| Baseline characteristic | All patients (n=28) |
|---|---|
| Gender (male/female) | 18/10 |
| Age (years) | 63.25±11.76 |
| Duration of MHD (months) | 25.50 (16.00–42.75) |
| BMI (kg/m) | 20.19 (18.78–21.52) |
| Dry weight (kg) | 58.50 (51.08–63.63) |
| Heart rate (beats/min) | 78.32±6.40 |
| Systolic blood pressure (mmHg) | 160.39±7.99 |
| Diastolic blood pressure (mmHg) | 84.68±7.25 |
| Diabetes mellitus | 15 (53.6%) |
| Hypertension | 28 (100%) |
| Previous myocardial infarction | 3 (10.7%) |
| Coronary artery disease | 14 (50.0%) |
| Stroke | 2 (7.1%) |
| Chronic glomerulonephritis | 7 (25.0%) |
| Hypertensive/renovascular disease | 3 (10.7%) |
| Diabetic kidney disease | 15 (53.6%) |
| Polycystic kidney | 3 (10.7%) |
| Others | 0 (0) |
| I | 0 (0) |
| II | 8 (28.6%) |
| III | 17 (60.7%) |
| IV | 3 (10.7%) |
| ACEI or ARB | 28 (100%) |
| Calcium channel blocker | 28 (100%) |
| Beta-blocker | 13 (46.4%) |
| α-blocker | 5 (17.9%) |
| Diuretics | 0 (0) |
| Antiplatelet | |
| Aspirin | 12 (42.9%) |
| Clopidogrel | 2 (7.1%) |
| Aspirin+clopidogrel | 1 (3.6%) |
| Aspirin+ticagrelor | 0 (0) |
| Cardiac troponin T | 0.030 (0.010–0.173) |
| CK-MB | 13.00 (10.00–15.75) |
| Potassium (K) (mmol/L) | 4.39±0.50 |
| Sodium (Na) (mmol/L) | 137.44±2.50 |
| Chlorine (Cl) (mmol/L) | 102.34±3.33 |
| Calcium (Ca) (mmol/L) | 2.06±0.18 |
| HGB (g/L) | 108.82±14.15 |
| Triglyceride (mmol/L) | 1.13±0.30 |
| Cholesterol (mmol/L) | 3.88±0.88 |
| HDL-C (mmol/L) | 1.12±0.41 |
| LDL-C (mmol/L) | 2.22± 0.68 |
| Albumin (g/L) | 36.85± 4.71 |
| Uric acid (μmol/L) | 397.40±90.45 |
| Phosphorus (P) (mmol/L) | 1.64±0.48 |
| PTH (pg/ml) | 155.36 (96.72–243.14) |
| AST(U/L) | 16.07±6.96 |
| ALT(U/L) | 13.14±6.14 |
| MHD – maintenance hemodialysis; BMI – body mass index; ACEI – angiotensin-converting enzyme inhibitor; ARB – angiotensin receptor blocker; NYHA – New York Heart Association; CK-MB – creatine kinase MB; HGB – hemoglobin; HDL-C – high-density lipoprotein-cholesterol; LDL-C – low-density lipoprotein-cholesterol; PTH – parathyroid hormone; AST – aspartate transaminase; ALT – alanine transaminase; CK-MB – creatine kinase MB. | |